This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Siemens VersaCell X3 Solution (Photo: Business Wire)

Siemens Healthcare Diagnostics further expanded its industry-leading clinical laboratory automation portfolio ¹ by unveiling VersaCell ® X3 Solution ² at the 2013 AACC and ASCLS Annual Meeting and Clinical Lab Expo in Houston, July 28 – August 1 (Booth #3449). The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers even more ways to help labs achieve the workflow benefits of automation without the space or budget considerations of a track-based solution. VersaCell X3 Solution’s arrival complements the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.

Siemens VersaCell X3 Solution (Photo: Business Wire)

Siemens VersaCell X3 Solution (Photo: Business Wire)

“Automation is essential to Martin Health System’s laboratory operations, helping staff optimize workflow, consistently achieve quality measures and deliver superior service to the physician community we support,” said Janet Frankenbery, BS, MT(ASCP) DLM, Corporate Director, Laboratory Services, Martin Health System. “As longtime users of several Siemens laboratory automation solutions, including multiple VersaCell systems, we are excited about the introduction of VersaCell X3 Solution and the additional benefits this advanced automation platform is positioned to deliver.”

Staffing challenges and widening access to medical care pushing testing volumes higher are increasing pressure on clinical laboratories to streamline operations and prepare for the future. ³ For lower- and mid-volume labs, whose budgets are often particularly constrained and where track-based automation may not be the right approach, VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.

A conveniently placed priority drawer on VersaCell X3 Solution, situated above existing routine sample drawers, provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Plus, modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems, increasing uptime so that labs can continue to deliver results to clinicians on time. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink™ Data Management System.

Stock quotes in this article: SI 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs